FindTrial
Sign In

BLU-451

DRUG2 trials

Sponsors

Blueprint Medicines Corp., Blueprint Medicines Corporation

Conditions

AdenocarcinomaAdvanced cancers with EGFR Exon20 insertions mutationsAntineoplastic AgentsBrain MetastasesBronchial NeoplasmsCarcinomaCarcinoma, BronchogenicCarcinoma, Non-Small-Cell Lung

Phase 1

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
TerminatedNCT05241873
Blueprint Medicines CorporationAdenocarcinoma, Antineoplastic Agents, Brain Metastases +17
Start: 2022-03-04End: 2024-07-31Updated: 2025-02-10
Phase 1/2 Study of BLU-451 in Advanced Cancers with EGFR exon20 Insertion Mutations
Not yet recruitingCTIS2022-502527-21-00
Blueprint Medicines Corp.Advanced cancers with EGFR Exon20 insertions mutations
Target: 28Updated: 2023-10-10

Related Papers

BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations
Molecular Cancer Therapeutics2026-05-13
Mobocertinib: Mechanism of action, clinical, and translational science
Clinical and Translational Science2024-03-0116 citations
Abstract C151: BLU-451 is a CNS-penetrant, wild-type-sparing EGFR inhibitor with broad coverage of uncommon EGFR mutations across structure-based subsets
Molecular Cancer Therapeutics2023-12-01
Emerging phase 1 data of BLU-451 in advanced NSCLC with EGFR exon 20 insertions.
Journal of Clinical Oncology2023-06-019 citations
Phase 1/2 study of BLU-451, a central nervous system (CNS) penetrant, small molecule inhibitor of EGFR, in incurable advanced cancers with <i>EGFR</i> exon 20 insertion (ex20ins) mutations.
Journal of Clinical Oncology2022-06-017 citations